Neogen
Price chart
Anonymous reader poll. Unscientific, not investment advice.
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 days.
- Recent price momentum is +42.1% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 5.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 2848 U.S. stocks StockVane covers.
Last computed: 2026-11-21 20:27 UTC
Data coverage: 5 of 6 factors. Missing data is not a zero score.
The radar needs all six factors. Available grades are shown below.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth C-
How fast revenue, profit and free cash flow are compounding.
| Revenue CAGR (3Y) | 1.9% | Better than 34% |
| Net income CAGR (3Y) | -7.1% | Better than 30% |
| Free cash flow CAGR (3Y) | -3.9% | Better than 34% |
Profitability C
How much profit the business keeps from each dollar of sales and capital.
| Gross margin | 46.9% | Better than 59% |
| Operating margin | -2.5% | Better than 19% |
| Net margin | -0.9% | Better than 24% |
| Return on equity | -0.4% | Better than 27% |
| Return on invested capital | 1.5% | Better than 32% |
Momentum B+
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -11.7% | Better than 46% |
| 6-month return | 18.5% | Better than 81% |
| 12-month return (ex latest month) | 109.4% | Better than 96% |
| Distance below 52-week high | 26.0% | Better than 49% |
Financial Health C+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 3.8x | Better than 80% |
| Debt to assets | 23.7% | Better than 50% |
| Interest coverage | 0.8x | Better than 28% |
| Free cash flow / net income | 90.3% | Better than 32% |
Analyst View B-
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 66.7% | Better than 41% |
| Upside to average target | 32.7% | Better than 52% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector. Background recomputation is scheduled every 6 hours; actual computation time is shown above, and source datasets have different reporting dates. Not investment advice or tailored to your financial situation.
Performance
Key statistics
Price & volume
- Prev close
- 10.85
- Open
- 10.76
- Day range
- 10.42 - 10.94
- Avg price
- 10.57
- Volume
- 3.04M
- Turnover
- 32.07M
- Turnover ratei
- 1.40%
- Volume ratioi
- 1.40
- Amplitudei
- 4.79%
- 52-week rangei
- 5.60 - 14.26
Valuation
- P/Ei
- -263.75
- P/E (TTM)i
- -40.58
- P/Bi
- 1.10
- EPSi
- -0.04
- Book value / shi
- 9.56
- Net profit
- -8.73M
- Net assets
- 2.09B
Share structure
- Market cap
- 2.30B
- Float capi
- 2.29B
- Shares out
- 218.31M
- Float sharesi
- 217.25M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
26.0% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-25.06M net over the window
Short interest
- Shares short
- 12.71M
- % of floati
- 5.82%
- Days to coveri
- 4.79
- As of
- 2026-10-30
Frequently asked questions
What is the current stock price of Neogen (NEOG)?
Neogen last traded at 10.55. This page shows a periodic quote snapshot. Check the displayed quote time.
What is Neogen's market cap?
About 2.30B.
What is the P/E ratio of Neogen?
The trailing twelve-month P/E is -40.58. The Valuation tab shows it against the stock's own five-year range.
Does Neogen pay a dividend?
Neogen does not currently pay a regular dividend.
Is Neogen a buy according to analysts?
The consensus of 3 analysts is a Buy rating, with an average 12-month price target of 14.00, which implies 32.7% upside from the current price. This is not investment advice.
What is Neogen's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Neogen a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Neogen discussion 0 comments